NCT03462641View on ClinicalTrials.gov

Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 9, 2018

Primary Completion Date

June 4, 2021

Study Completion Date

June 4, 2021

Conditions
Parkinson Disease
Interventions
DRUG

Flumazenil

1mg in 10cc normal saline

DRUG

Placebo

10 cc normal saline

Trial Locations (1)

48106

University of Michigan Functional Neuroimaging, Cognitive and Mobility Laboratory, Ann Arbor

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

University of Michigan

OTHER

NCT03462641 - Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm | Biotech Hunter | Biotech Hunter